PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
Phase of Trial: Phase II
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs Depatuxizumab (Primary) ; Nivolumab (Primary) ; Ramucirumab (Primary) ; Rilotumumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms PANGEA; PANGEA-IMBBP
- 29 Apr 2019 Planned End Date changed from 1 Oct 2018 to 1 Feb 2022.
- 29 Apr 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Feb 2020.
- 28 Jan 2019 Results evaluating effect of ramucirumab on clinical activity of FOLFIRI as 3rd line therapy in metastatic gastric Cancer patients were published in the Investigational New Drugs.